Background
==========

Type 2 diabetes (T2D) is characterized by hyperglycemia due to insulin resistance and is accompanied by a failure of β cells to produce sufficient insulin. In the United States, the prevalence of diabetes has risen 40% from 1990 to 1999 \[[@B1]\]. This increase in T2D has been attributed to the recent rise in obesity. The correlation between diabetes and obesity has been shown in numerous epidemiological studies \[[@B2],[@B3]\] although the mechanisms underlying this phenomenon are largely unknown. One current hypothesis proposes that malnutrition in the fetus can lead to the developmental impairment of pancreatic β cells, termed a \"thrifty phenotype\" and that later in life, these children are more susceptible to diabetes \[[@B4]\].

Candidate gene studies in T2D have implicated numerous gene variants that decrease disease risk, such as *PPARG*(P12A) \[[@B5]\], and others that increase disease risk, such as *KCNJ11*(E23K) \[[@B6]\]. One of the strongest T2D-associated loci has been mapped to the transcription factor *TCF7L2*\[[@B7]\], (odds ratio ≈1.7) and this association has been replicated in numerous subsequent studies \[[@B8]-[@B20]\].

In addition to single nucleotide polymorphisms (SNPs), genomic insertion/deletion polymorphisms may also influence disease risk. One such example is the deletion polymorphism in the angiotension-converting enzyme (ACE), which has been shown to confer increased risk of coronary artery disease \[[@B21]\]. Recently the HapMap genotype data was used to search for segregating deletions by examining physically clustered failed SNP genotype assays, Mendelian inconsistencies, and departures from Hardy-Weinberg disequilibrium \[[@B22]\]. Five hundred and forty-one deletions were identified ranging in size from 1 to 754 kb. One predicted 10.3 kb deletion polymorphism was located under a widely replicated obesity linkage peak on chromosome 7q22-q36 \[[@B23]-[@B32]\] between the *EXOC4*and *LRGUK*genes. Importantly, linkage to metabolic syndrome has also been reported for the Family Heart Study cohort in the 7q32 region \[[@B33]\].

The aim of this study was to examine SNPs and a chromosomal deletion on chromosome 7q32 in a sample of families exhibiting linkage to obesity and metabolic syndrome in the region \[[@B27],[@B33]\]. Due to the presence of a gene (*EXOC4*) that is part of the exocyst complex (Exo70), which is involved in insulin-stimulated glucose transport, association to T2D risk and blood glucose levels was hypothesized. In addition, we examined the association between the minor allele of the SNP rs7903146 \[[@B7]\] within the transcription factor *TCF7L2*and T2D disease risk. Each polymorphism\'s association to T2D risk was examined in a large Caucasian subset of the Family Heart Study (FHS) population comprising 2,396 participants (205 T2D cases). In addition to T2D disease affection status, fasting plasma glucose (FPG) was also examined among non-diabetics.

Methods
=======

Subjects
--------

The National Heart, Lung and Blood Institute (NHLBI) Family Heart Study (FHS) recruited families from four existing study centers located in Forsyth County, NC; Framingham, MA; Minneapolis, MN; and Salt Lake City, UT. Approximately one half of the families recruited from these study centers were at high risk for coronary heart disease (CHD) while the other half were selected randomly from their respective study populations.

The body mass index (BMI) SNP fine mapping study genotyped 2,421 FHS participants including 158 diabetics. For the deletion study, 416 of these, including two diabetics, either did not genotype for the deletion or did not have sufficient DNA for the deletion study. Therefore, an additional 182 FHS samples, including 49 diabetics, not originally included in the SNP analysis were typed for the deletion. In total, 2,603 participants, including 207 diabetics, were studied.

T2D diabetes was defined by self-report of diabetes diagnosis and limited to those with an age at diagnosis greater than 25. The controls used were participants recruited as part of FHS who did not report a diagnosis of diabetes. An enzymatic (glucose-oxidase) method (Kodak Ektachem 700 Analyzer, Rochester, NY) was used to measure fasting serum glucose as mg/dL. This study was approved by the institutional review boards (IRB) of the participating institutions and appropriate informed consent was obtained.

Deletion Detection
------------------

Deletions were detected in the study population using real-time polymerase chain reaction (RT-PCR). To accurately type deletion variants, we designed primers to amplify regions within the proposed chromosomal deletion on chromosome 7q32. We performed TaqMan RT-PCR assays, using a VIC-labeled probe for a known diploid gene *PMP22*(NM_153321) as a control reference and a VIC-labeled probe (Applied Biosystems, Foster City CA) for the experimental region, each run simultaneously. Each DNA sample was run in quadruplicate for each TaqMan assay on the PRISM^®^7900 HT Sequence Detection System. The cycles-to-threshold (C~t~) was determined for each assay separately, and the difference between the average Ct for the experimental probe and control assays (ΔC~t~) was used to infer the presence of zero, one or two copies of the deleted segment. For the examined FHS study sample, the average ΔC~t~values clustered into three discrete groups, including one group showing amplification of the control locus and no amplification of the experimental locus. Treating each genotype cluster as \'+/+\' (wildtype), \'+/-\' and \'-/-\'DNA samples could be assigned a standard genotype (i.e. 11, 12, 22). A small number of individuals whose ΔC~t~value fell outside of the three genotype clusters (*n=*69, 2.8%) were coded as missing genotypes.

SNP Genotyping
--------------

SNPs in the genes neighboring the deletion were genotyped as part of a fine-mapping study of BMI. Thirty-nine Tag SNPs were selected using the HapMap tagger algorithm in the region between 132,552,341 (rs6467475) and 133,619,534 (rs1421483). In addition, the SNP rs7903146, located on chromosome 10 at 114,748,089 bp within an intron of the gene *TCF7L2*(NM_030756), was genotyped. The TCF7L2 SNP was typed using the TaqMan^®^technology developed by Applied Biosystems (Foster City, CA) using the PRISM^®^7900 HT Sequence Detection System. The 39 HapMap derived SNPs were genotyped using the Illumina Golden Gate^®^assay method, through the Illumina Fast-Track Genotyping service. Mendelian inconsistencies were identified using INFER within the PEDSYS software package \[[@B34]\], and genotypes in the pedigrees where inconsistencies were found were removed.

Linkage Disequilibrium (LD) Assessment
--------------------------------------

We assessed the LD between the chromosomal deletion obtained by RT-PCR, using deletion genotypes (\'+/+\', \'+/-\', \'-/-\') coded as 11, 12 and 22 and adjacent SNPs. The software program Haploview \[[@B35]\] was used to estimate the pairwise LD (*r*^2^) between the chromosomal deletion and nearby SNPs within 500 kb.

Statistical Analysis
--------------------

To evaluate the relationship of polymorphisms to T2D, dominant and recessive modeling of the minor allele was performed in a logistic regression implemented with a generalized estimating equation and adjusted for TCF7L2 minor allele, BMI at age 25 (based on participants\' self report), study center, age, age^2^, age^3^, sex, and smoking history (never/ever). The relationship to T2D for the *TCF7L2*SNP (rs7903146) was modeled as a dominant genetic effect (major homozygotes = 0, heterozygotes and minor homozygotes = 1) as previously reported \[[@B7]\] and the deletion polymorphism modeled as a recessive genetic effect (\'+/+ wildtype\' and \'+/-\' = 0 and \'-/-\' = 1) using the same covariates described above. As the FHS sample included prevalent diabetics, analyses of diabetes status were adjusted for an age variable that was defined as the age at diagnosis for diabetic cases and the age at clinical examination for non-diabetic controls. No correction for multiple testing was used in these analyses and, therefore, all p-values are reported as nominal p-values.

In addition to diabetes status, fasting glucose (mg/dL) levels were analyzed in non-diabetics using a linear GEE regression model adjusted for BMI, study center, age, age^2^, age^3^, smoking history status and sex. The deletion and TCF7L2 polymorphism were analyzed together in the same model. In this regression model, measurements of BMI and age at the time of examination were used.

Results
=======

Clinical characteristics of the study subjects are shown in Table [1](#T1){ref-type="table"}. The mean age at examination of the diabetics was 61.57 with a range from 25.6 to 84.7 and of the non-diabetics participant\'s mean age was 52.0 with a range from 25.2 to 91.0. Both the BMI at examination (*p*= 10^-4^) and the reported BMI at age 25 (*p*\< 10^-4^) were significantly different between diabetics and non-diabetics. However, the age at examination of non-diabetics was not different from the age at diagnosis of diabetes among the diabetics (*p*= 0.82).

###### 

Characteristics of the study population

  --------------------------------------------- -------------- -----------------
                                                Diabetics      Non-diabetics
                                                               
  *N*genotyped for deletion                     205            1982
  *N*genotyped for SNPs                         158            2263
  Total studied for either SNPs or deletion\*   207            2396
  Male                                          55.1%          46.7%
  Age at onset of diabetes (years)              51.7 ± 11.6    \-
  Age at examination (years)                    62.2 ± 9.9     51.8 ± 13.4\*\*
  BMI (kg/m^2^) at examination                  30.0 ± 5.1     27.5 ± 5.8\*\*
  BMI (kg/m^2^) at age 25                       24.5 ± 4.9     22.9 ± 3.6\*\*
  Fasting glucose (mg/dL)                       173.9 ± 70.1   95.4 ± 16.1\*\*
  Center (%):                                                  
  Forsyth County, North Carolina,               22.2           22.5
  Minneapolis, Minnesota                        24.7           28.0
  Framingham, Massachusetts                     19.8           22.0
  Salt Lake City, Utah                          33.3           27.5
  --------------------------------------------- -------------- -----------------

\*means and frequencies correspond to sample with either deletion or SNP genotyping

\*\* p \< 10^-4^

Deletion Polymorphism
---------------------

Table [2](#T2){ref-type="table"} lists the sequences for the control (*PMP22*) and deletion detection primers and probes. A total of 2,198 study participants were assayed and the average ΔC~t~was used to generate three genotype clusters (Figure [1](#F1){ref-type="fig"}). The deletion was present in 52.7% (*n=*1,152) of the study population with a deletion allele frequency of 31.2% and was in Hardy-Weinberg equilibrium (*p*= 0.85).

###### 

Primer and probe sequences used in the RT-PCR deletion assay

  Gene              Region                                     
  ----------------- ------------------------------- ---------- --------------------------------
  PMP22 (Control)   chr17:15,074,941--15,075,005               
                                                    Primer 1   CCCTTCTCAGCGGTGTCATC
                                                    Primer 2   ACAGACCGTCTGGGCGC
                                                    Probe      VIC -- TTCGCGTTTCCGCAAGAT
                    chr7:133,441,108--133,441,133              
                                                    Primer 1   GCCTTGCCCGAGTACATATT
                                                    Primer 2   AGAGTTGGCCTCTGTCCCTA
                                                    Probe      VIC-CAGCTGGTGTTACCAGTAAAGGCCCT

![**Insertion/deletion genotype clusters**. Deletion genotype clusters as measured by real-time PCR. Individuals outside of the clusters, defined by the black boxes, were marked with an unknown genotype.](1471-2350-9-46-1){#F1}

Diabetes risk results for the deletion versus the TCF7L2 polymorphism are shown in Table [3](#T3){ref-type="table"}. In the total study sample, there was a protective effect of the homozygous deletion genotype on diabetes (*p*= 0.016 odds ratio (OR) = 0.47, 95% CI 0.25--0.87). In addition, BMI at age 25 was shown to be a strong risk factor for diabetes (*p*\< 10^-4^, beta estimate = .09, OR for a 1 unit BMI increase at age 25 = 1.09). In the total study sample, 5.4% (*n*= 11) of the diabetics were homozygous for the deletion as compared to 10.2% (*n*= 203) of the non-diabetics.

###### 

Logistic GEE results incorporating both polymorphisms

  Diabetes Status                                                                        
  ----------------- --------------------- ------------------------ --------------------- -----------
                    Homozygous deletion   rs7903146 minor allele                         
                                                                                         
                    OR \[95% CI\]         *p-value*                OR \[95% CI\]         *p*-value
                                                                                         
  Both sexes        0.47 \[0.25,0.87\]    0.016                    1.31 \[0.95,1.81\]    0.099
  Women             0.57 \[0.22,1.52\]    0.26                     1.63 \[1.02,2.59\]    0.039
  Men               0.45 \[0.20,1.05\]    0.064                    1.14 \[0.76, 1.72\]   0.53

Results from logistic GEE models incorporating the deletion genotyping and rs7903146, including sex-stratified results. Odds ratios (OR), 95% confidence interval (95% CI) and *p*-values are reported.

\*205 cases, 1982 controls -- adjusted for BMI at age25, onset age for cases (w/square and cubed)

When stratified by sex, the protective effect of the deletion on diabetes was stronger in men (*p*= 0.064, OR = 0.45, 95% CI 0.2--1.05) than in women (*p*= 0.26, OR = 0.57, 95% CI 0.22--1.52) with BMI at age 25 remaining a strong risk factor for diabetes in each gender (*p*\< 10^-4^). In men, 5.4% (*n*= 6) of the diabetics were homozygous for the deletion as compared to 11.4% (*n*= 107) of the non-diabetics. In women, the individuals homozygous for the deletion represented 5.4% (*n*= 5) of the diabetics and 9.2% (*n*= 96) of the non-diabetics, although the effect was not statistically significant.

In addition, we tested the effect of the deletion and the *TCF7L2*SNP on fasting glucose levels among non-diabetics stratified by sex (see Table [4](#T4){ref-type="table"}). In an analysis of both sexes combined, the TCF7L2 minor allele was associated with a 1.3 mg/dL higher mean glucose level (p = 0.045), whereas the deletion polymorphism did not have a significant effect on glucose levels. Men homozygous for the deletion polymorphism had a statistically significant decrease in fasting glucose levels (*p*= 0.038, β-estimate = -2.57 mg/dL) while the *TCF7L2*SNP had a modest increase in fasting glucose levels (*p*= 0.089, β-estimate = 1.91 mg/dL). Neither polymorphism had a significant effect on fasting glucose in women.

###### 

GEE results for fasting glucose levels (mg/dl)

  ------------ --------------------- ------------------------ --------------- -----------
               Homozygous deletion   rs7903146 minor allele                   
                                                                              
               beta-estimate         *p-value*                Beta-estimate   *p*-value
                                                                              
  Both sexes   -0.50                 0.57                     1.33            0.045
  Women        1.89                  0.118                    0.77            0.283
  Men          -2.57                 0.038                    1.91            0.089
  ------------ --------------------- ------------------------ --------------- -----------

Results from GEE models for the deletion genotyping and rs7903146 modeled together including sex-stratified results.

SNP Association
---------------

Association analyses to diabetes using SNPs in the *EXOC4*and *LRGUK*gene regions identified multiple polymorphisms with evidence for association (Table [5](#T5){ref-type="table"}). Seven SNPs (rs3823572, rs12531707, rs11770757, rs7457999, rs6953590, rs12670589, and rs1421483) demonstrated significant association (p = 0.01) to fasting glucose. Using a dominant modeling of the minor allele, the SNP rs12531707 in an *EXOC4*intron produced an odds ratio for diabetes of 1.79 (p = 0.009). The SNP in strongest LD with the deletion, rs7457999, exhibited a protective effect for diabetes. Using a recessive modeling of the minor allele, the SNP rs12670589 in a *LRGUK*intron produced an OR for diabetes of 2.02 (p = 0.002). Other SNPs in both *EXOC4*and *LRGUK*produced larger ORs for the recessive model, but the results were based on a small number of homozygous minor allele carriers. For example, rs11770757 produced an OR = 11.9 based on two homozygous minor allele carriers each in cases and controls, and the results may be spurious. We have presented all recessive results for which the model converged in the hopes that replication studies in larger samples of diabetics will examine these SNPs.

###### 

SNP association to diabetes in region surrounding deletion

  SNP              bp position   Gene                Dominant OR   Dominant p-value   Recessive OR   Recessive p-value
  ---------------- ------------- ------------------- ------------- ------------------ -------------- -------------------
  rs6467475        132552341                         1.04          0.85               1.29           0.30
  rs11979455       132558191                         1.22          0.24               1.46           0.20
  rs6979285        132564427                         0.70          0.22                              
  rs6951889        132566505                         0.73          0.09               0.90           0.77
  rs10262862       132606574     *EXOC4*             1.03          0.88               1.36           0.19
  rs13242614       132616839     *EXOC4*             0.93          0.76               2.67           0.03
  rs1922420        132647772     *EXOC4*             0.94          0.74               1.07           0.86
  rs6978272        132738579     *EXOC4*             1.03          0.88               0.76           0.71
  rs13241123       132786047     *EXOC4*             0.83          0.29               0.79           0.42
  rs6971417        132816709     *EXOC4*             1.45          0.04               1.42           0.33
  rs13237737       132842959     *EXOC4*             1.15          0.71               4.00           0.18
  rs10755879       132910055     *EXOC4*             0.71          0.14               2.10           0.17
  rs6954842        132938673     *EXOC4\|KIAA1699*   1.19          0.35               1.23           0.42
  rs1362736        133060409     *EXOC4\|KIAA1699*   1.00          1.00               1.59           0.47
  rs17167240       133075208     *EXOC4\|KIAA1699*   0.83          0.34               0.44           0.11
  rs9649047        133084054     *EXOC4\|KIAA1699*   0.98          0.93               1.26           0.72
  rs11772444       133104414     *EXOC4\|KIAA1699*   1.51          0.02               1.72           0.11
  rs13222377       133116886     *EXOC4\|KIAA1699*   0.99          0.97               0.89           0.79
  rs17167267       133119649     *EXOC4\|KIAA1699*   1.15          0.56                              
  rs748754         133159609     *EXOC4\|KIAA1699*   1.09          0.60               0.81           0.52
  rs12155007       133235969     *EXOC4\|KIAA1699*   0.74          0.31               4.79           0.05
  rs4266574        133277976     *EXOC4\|KIAA1699*   0.80          0.24               0.29           0.04
  rs2971970        133294318     *EXOC4\|KIAA1699*   1.42          0.07               1.48           0.25
  **rs3823572**    133331141     *EXOC4\|KIAA1699*   0.89          0.53               0.58           **0.01**
  **rs12531707**   133378771     *EXOC4\|KIAA1699*   1.79          **0.009**          1.15           0.49
  rs6955114        133387570     *EXOC4\|KIAA1699*   1.26          0.20               0.97           0.90
  rs6971064        133390804     *EXOC4\|KIAA1699*   1.17          0.40               0.87           0.81
  **rs11770757**   133398486     *EXOC4\|KIAA1699*   0.71          0.33               11.87          **0.006**
  **rs7457999**    133398775     *EXOC4\|KIAA1699*   0.62          **0.01**           0.58           0.22
  rs10246346       133415861                         1.04          0.86               0.79           0.76
  Deletion                                                                                           
  rs13246630       133472159     *LRGUK*             1.36          0.09               1.27           0.27
  **rs6953590**    133487840     *LRGUK*             1.52          **0.01**           1.86           **0.006**
  rs17761994       133494082     *LRGUK*             1.23          0.35                              
  **rs12670589**   133495637     *LRGUK*             1.30          0.14               2.03           **0.002**
  rs892984         133502721     *LRGUK*             0.64          0.10               0.92           0.92
  rs1222430        133566300     *LRGUK*             0.73          0.24               1.08           0.93
  rs1421477        133569572     *LRGUK*             1.15          0.51                              
  rs1450890        133584737     *LRGUK*             0.86          0.41               1.31           0.33
  **rs1421483**    133619284                         1.01          0.97               3.93           **0.009**

Within the total study population the SNP rs7903146, located within an intron of the gene *TCF7L2*(NM_030756), had a minor allele frequency of 31%. In a dominant model, the *TCF7L2*SNP was modestly associated with diabetes risk (*p*= 0.099, OR = 1.31, 95% CI 0.95--1.81). In the total study sample, 57.5% (*n*= 119) of the diabetics were minor risk allele carriers as compared to 51.9% (*n*= 1243) of the non-diabetics.

When stratified by sex, the minor allele of the *TCF7L2*SNP was associated with a large increased risk for T2D in women (*p*= 0.039, OR = 1.63, 95% CI 1.02--2.59) whereas no effect was seen in men (*p*= 0.53, OR = 1.14, 95% CI 0.76--1.72). In women, 63.4% (*n*= 59) of the diabetics were minor allele risk carriers compared to 50.6% (*n*= 646) of the non-diabetics. In men, 52.6% (*n*= 60) of the diabetics were minor allele risk carriers compared to 52.6% (*n*= 597) of the non-diabetics.

Finally, the linkage disequilibrium (*r*^2^) between the deletion polymorphism and the thirty-nine surrounding SNPs genotyped in the total study population is displayed in Figure [2](#F2){ref-type="fig"}. The deletion polymorphism exhibited modest LD with SNP rs7457999 (*r*^2^= 0.37) and rs13246630 (*r*^2^= 0.20).

![**LD structure surrounding the insertion/deletion polymorphism**. Linkage disequilibrium (*r*^2^) of the deletion polymorphism (\'Deletion\') and surrounding genotyped SNPs within the FHS study population. The legend above the LD plot shows the location of the genes *EXOC4*and *LRGUK*(FLJ32786).](1471-2350-9-46-2){#F2}

Discussion
==========

The rs7903146 SNP in the *TCF7L2*gene represents perhaps the most important gene polymorphism implicated in type 2 diabetes, since it is a relatively common variant that confers increased risk for diabetes and this association has been replicated across numerous independent samples \[[@B7],[@B9],[@B10],[@B13],[@B17],[@B20],[@B36]\]. In this study, we report a novel deletion polymorphism on chromosome 7q32 that confers a protective effect for diabetes, with homozygous deletion carriers having a 53% reduced risk of diabetes compared to carriers of the non-deleted region. In addition, we demonstrate an increased risk associated with the minor allele of the *TCF7L2*SNP that is identified primarily in women, but not men of the Family Heart Study. In this sample, the statistical evidence for association to T2D of the homozygous deletion, although it reduces rather than increases risk, was comparable to that of the *TCF7L2*SNP. Several nearby SNPs in the 7q32 region also show significant association to T2D, and this may represent linkage disequilibrium among these various polymorphisms. Finally, we report that non-diabetic male homozygous deletion carriers had significantly lower fasting glucose levels, suggesting that the risk for T2D may be mediated by reduced glucose levels.

The region implicated by the deletion and SNP polymorphisms reported here is located between the genes *EXOC4*(NM_021807) and *LRGUK*(NM_144648). Interestingly, *EXOC4*is a large gene and its product is part of the exocyst complex 70 (Exo70) that assembles at the plasma membrane of adipocytes in response to insulin and has been reported to play a role in docking and tethering the glucose transporter 4 (*GLUT4*) vesicle to the plasma membrane \[[@B37],[@B38]\]. *GLUT4*accounts for much of the insulin-stimulated glucose transport in muscle and adipose tissue \[[@B38],[@B39]\]. Inoue et al. (2003) report variability in insulin-stimulated glucose uptake with Exo70 variants, and *EXOC4*was shown to interact with both the Exo70 wildtype and the amino-terminal fragment of Exo70, which may block the insulin-stimulated assembly of exocyst complex at the plasma membrane. *EXOC4*has also been shown to be involved the initial docking of insulin vesicles to the cell membrane of pancreatic β cells and is thought to play a role in regulating insulin vesicle exocytosis in response to a glucose stimulus \[[@B40]\]. The potential for this gene to influence diabetes and glucose levels prompted us to evaluate the association to these traits. Though the deletion polymorphism does not seem to overlap with *EXOC4*, transcriptional binding elements could exist downstream of the gene within the region of the deletion that influence transcription. Finally, differences in *EXOC4*transcription levels could affect glucose stimulated insulin release as well as insulin induced cellular uptake of glucose resulting in the decreased fasting plasma glucose levels found for homozygous deletion carriers in non-diabetics.

Findings in other cohorts also support the presence of a gene(s) influencing diabetes risk in this region. Genome-wide associations for diabetes were recently performed by the Wellcome Trust Case Control Consortium (WTCCC) \[[@B41]\] and the Diabetes Genetics Initiative (DGI) \[[@B42]\], and the results are publicly available. We examined association results for the SNPs in the region spanning the EXOC4 gene, the deletion, and the LRGUK gene, which included 202 SNPs in the WTCCC and 128 SNPs in the DGI studies. From the Wellcome Trust results, we identified 37 SNPs with association p-values less than 0.05, and from the DGI, we identified ten SNPs with association p-values less than 0.05. The best p-value identified in the Wellcome Trust results in this region was 0.0004 at rs6963221 in EXOC4. In the DGI results, the best p-value was 0.015 at rs17167492 in LRGUK. These results from two independent samples lend support for polymorphisms in the region influencing diabetes risk.

One limitation of our study is the self-reported diabetes status. Individuals used in our fasting glucose analysis may have been diagnosed with diabetes after FHS study enrollment or may have failed to report themselves as having been diagnosed for diabetes and, therefore, our analysis of fasting glucose may have included undiagnosed diabetics in the non-diabetic study population. Nevertheless, the glucose levels analyzed were unmedicated measurements.

Conclusion
==========

In this study, we report a large novel deletion polymorphism that is associated with reduced risk for T2D and several SNPs associated with either increased or decreased risk for T2D on chromosome 7q32 located within a widely replicated BMI linkage region \[[@B23]-[@B32]\]. In addition, we demonstrate that non-diabetic males that are homozygous for the deletion polymorphism have lower levels of fasting glucose, which may contribute to protection from T2D. Furthermore, when examined together, the deletion polymorphism offers an effect, albeit protective, comparable to the widely replicated risk associated with the SNP rs7903146 within the transcription factor *TCF7L2*. Since these polymorphisms are in an intergenic region, their relation to nearby gene(s) is speculative and further research will need to be conducted to elucidate the mechanism by which they influence risk for T2D. Ultimately, understanding this mechanism(s) could shed light on the poorly understood relationship between obesity and diabetes and may suggest pathways involved in reducing glucose levels and risk for diabetes.
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